Dr. Gerald A. Higgins is Research Professor of Computational Medicine and Bioinformatics at the University of Michigan Medical School. His background includes chief of molecular neurobiology at the NIH, VP of R&D of Laerdal Medical Corporation, CIO of MedStar Health Hospital network, several startup companies, and VP of pharmacogenomic science at Assurex (now Myriad Genetics). His research combines expertise in pharmacogenomics, psychiatry, and computational analysis to understand human brain networks involved in psychotropic drug response. His recent research has demonstrated that HDAC inhibitors such as valproic acid work in human CNS to change astrocytes into neural progenitor cells following injury, by altering nuclear shape into a relaxed pluripotent state, activating transcriptional programs of neurogenesis. His research has also demonstrated the plasticity of human CNS network topology in addiction and resiliency. His work using artificial intelligence emphasizes pharmacology expertise combined with development of UX (user interface) design to enhance understanding by experimental biologists.